Imiquimod, a TLR-7 ligand, is currently approved for BCC, AK, and Condyloma acuminatum, but there is an emerging interest in using imiquimod for other skin cancers, infections, and inflammatory skin conditions. This evidence concerns the gene TLR7 and skin basal cell carcinoma.